Medincell (Euronext Paris: MEDCL), the France-based developer of long-acting injectable drug-delivery technology, has secured a second United States Food and Drug Administration-approved medicine through its partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), following the October 9, 2026 approval of Weltruza (olanzapine) for extended-release injectable suspension. The treatment is approved for adults with schizophrenia and represents the first once-monthly subcutaneous long-acting injectable formulation of olanzapine, with no requirement for loading doses, oral supplementation or routine post-injection observation.
The approval moves Weltruza, previously developed as TEV-749, from clinical development into the commercial launch phase and creates another potential recurring royalty source for Medincell. Teva Pharmaceuticals expects to introduce the product in the United States in the coming weeks, offering three once-monthly strengths corresponding to established oral olanzapine dosing ranges. Under the companies’ agreement, Medincell is entitled to mid- to high-single-digit royalties on worldwide net sales and a $4 million regulatory milestone triggered by the United States approval.
The commercial significance extends beyond introducing another schizophrenia medication. Olanzapine is an established antipsychotic, but its use as a long-acting injectable has historically faced practical limitations associated with post-injection delirium/sedation syndrome, or PDSS, and the mandatory observation requirements attached to an existing intramuscular formulation. Weltruza’s approved administration model removes the requirement for routine post-injection monitoring, potentially improving convenience for healthcare providers and patients while preserving the systemic safety considerations associated with olanzapine.
For Medincell, the regulatory decision also demonstrates that its sustained-release technology can support more than one approved commercial medicine. Its first partnered product, Uzedy, received United States approval in 2023 and has since generated increasing sales and royalty income. Weltruza now provides a second opportunity to convert the company’s drug-delivery platform into recurring commercial revenue, although its eventual contribution will depend on Teva’s launch execution, prescribing adoption and payer access.
Why does Weltruza’s FDA approval represent an important change in long-acting olanzapine treatment?
Weltruza combines the established antipsychotic olanzapine with Medincell’s SteadyTeq sustained-release technology to deliver the medicine through subcutaneous injections administered once monthly. The product will be available in 318 mg, 425 mg and 531 mg strengths, corresponding to oral olanzapine daily dosing levels of 10 mg, 15 mg and 20 mg, respectively. These are formulation-specific dose equivalents rather than interchangeable milligram quantities, reflecting the controlled release of medicine over an extended period.
One of the principal clinical advantages identified by Teva is the ability to begin treatment without additional oral olanzapine supplementation or a separate loading-dose regimen. Some long-acting antipsychotics require additional medication during initiation or specific injection schedules to establish therapeutic exposure. Removing those requirements could simplify certain aspects of treatment initiation, particularly for patients whose clinicians have already established that olanzapine is an appropriate therapy.
The route of administration provides another distinction. Weltruza is administered subcutaneously, whereas Zyprexa Relprevv, an existing extended-release olanzapine product, is administered intramuscularly and carries specific restrictions associated with PDSS. These differences could influence treatment-site requirements and patient preferences, although convenience alone does not establish superior clinical outcomes.
Long-acting antipsychotics are particularly relevant in schizophrenia management because inconsistent medication use can contribute to symptom recurrence and psychiatric hospitalisation. However, improved dosing convenience does not automatically demonstrate better adherence, fewer relapses or reduced healthcare expenditure in routine clinical practice. Those outcomes will need to be evaluated through real-world utilisation and follow-up data as Weltruza enters commercial use.
How does Weltruza address the post-injection monitoring barrier associated with older olanzapine injections?
The absence of mandatory routine post-injection monitoring is one of the most commercially important features of Weltruza’s approval. Zyprexa Relprevv requires patients to remain under observation for at least three hours following administration because of the risk of PDSS, a potentially serious reaction associated with unexpectedly high olanzapine exposure after injection. The existing product is also subject to a restricted distribution programme involving certified healthcare facilities and associated safety procedures.
These requirements can complicate treatment delivery by increasing appointment duration, limiting eligible administration locations and imposing additional operational demands on healthcare providers. For a treatment intended to support long-term maintenance therapy, repeated lengthy observation appointments can present practical challenges. A formulation that does not carry the same routine observation requirement may therefore be easier to incorporate into certain outpatient psychiatric services.
Nevertheless, the regulatory distinction should not be interpreted as proof that PDSS cannot occur with Weltruza. Teva’s approved safety information states that PDSS has occurred with another extended-release intramuscular olanzapine medicine and that it is not known whether the syndrome can occur with Weltruza. Patients and healthcare professionals must therefore remain attentive to relevant symptoms even though a specific routine post-injection monitoring period is not required.
The SOLARIS clinical programme did not identify PDSS cases among participants receiving the investigational formulation during the disclosed evaluations. This finding supported the safety assessment underlying the approval, but the absence of observed events does not establish zero risk, particularly for uncommon complications that may become more apparent after broader commercial exposure. Post-marketing surveillance will remain important in determining the treatment’s longer-term safety profile across a more diverse population.
The comparison with Zyprexa Relprevv is therefore primarily about approved administration requirements and observed safety findings, rather than a demonstrated head-to-head superiority advantage. The two formulations have different administration characteristics, and clinicians will still need to consider the individual patient’s clinical status and the full prescribing information when evaluating treatment options.
What did the Phase 3 SOLARIS trial demonstrate about Weltruza’s efficacy in schizophrenia?
The FDA approval was supported by the Phase 3 SOLARIS clinical programme, which evaluated the efficacy, safety and tolerability of the extended-release olanzapine formulation in adults diagnosed with schizophrenia. The pivotal efficacy portion was an eight-week, multicentre, randomised, double-blind, placebo-controlled study in which 675 patients were randomised across three active-dose groups and placebo. A subsequent open-label period provided additional longer-term safety information.
The primary endpoint measured changes from baseline in the Positive and Negative Syndrome Scale, commonly known as PANSS, which assesses the severity of schizophrenia symptoms. Teva reported that all three active-dose groups demonstrated statistically significant improvements compared with placebo at Week 8. The placebo-adjusted differences in PANSS total score improvement were approximately 9.7 points for the highest dose, 11.3 points for the middle dose and 9.7 points for the lowest dose, with reported p-values below 0.0001.
These results provide controlled evidence that the long-acting formulation reduces schizophrenia symptom severity over the evaluated acute treatment period. Importantly, the findings do not establish that Weltruza is more effective than oral olanzapine or other long-acting antipsychotic treatments, since SOLARIS was not designed as a direct comparative superiority trial against those products. The efficacy conclusions must therefore remain tied to the placebo-controlled study and the precise outcomes assessed.
The programme also met key secondary endpoints involving clinician-rated illness severity and personal and social functioning. Teva reported statistically significant improvements in Clinical Global Impression-Severity scores and Personal and Social Performance Scale scores across the three active-dose groups. These findings add relevant evidence because schizophrenia treatment goals extend beyond symptom reduction to include functioning and the ability to manage everyday activities.
However, short-term improvements in symptom and functioning scales are not equivalent to direct evidence of fewer hospitalisations, lower relapse rates or sustained long-term functional recovery. Such outcomes may be influenced by adherence, background care, illness history and other patient-specific factors. Real-world evidence and longer follow-up will therefore be needed to determine how the treatment performs in routine maintenance care.
What safety limitations remain despite the absence of mandatory post-injection observation?
Weltruza retains important safety considerations associated with systemic olanzapine exposure. In the SOLARIS programme, the most frequently reported adverse events included weight increase, somnolence, headache, constipation and injection-site reactions. Teva stated that the overall systemic safety profile was consistent with established olanzapine formulations, including clinically significant weight gain and metabolic changes.
Weight gain was a particularly notable finding during the controlled efficacy period. Data previously presented from SOLARIS showed weight increase reported as a treatment-emergent adverse event in 35% of participants receiving active treatment, compared with 8% receiving placebo. These figures describe reported adverse events rather than the proportion of patients meeting a specific percentage-weight-gain threshold, and they should not be interpreted as interchangeable measures.
Olanzapine is associated with metabolic risks that include hyperglycaemia, dyslipidaemia and weight gain, making metabolic assessment and continued monitoring important considerations during treatment. The long-acting formulation does not eliminate these established pharmacological risks simply because the medicine is administered less frequently. The potential convenience advantage of once-monthly dosing must therefore be considered separately from the broader safety profile of the active ingredient.
Weltruza also carries the boxed warning concerning increased mortality in elderly patients with dementia-related psychosis, consistent with the class warning for antipsychotic medicines. The product is not approved for treating dementia-related psychosis, and the safety information additionally addresses potentially serious reactions including neuroleptic malignant syndrome, tardive dyskinesia and orthostatic hypotension. These established warnings remain clinically relevant regardless of the formulation’s administration schedule.
The post-marketing safety experience will be especially important because clinical trials may not capture rare adverse events or fully represent patients with multiple medical conditions and complex medication regimens. The approved product offers a different administration model, but its longer-term risk-benefit assessment will continue to depend on the clinical characteristics of the patients receiving it.
How does Weltruza strengthen Medincell’s commercial partnership with Teva Pharmaceutical Industries?
Weltruza becomes the second FDA-approved medicine developed through the Medincell and Teva collaboration, following Uzedy, the extended-release risperidone injectable approved in April 2023. Both products use Medincell’s sustained-release drug-delivery technology, which Teva licenses under the SteadyTeq name. Their approvals provide commercial evidence that the underlying technology can support different antipsychotic active ingredients.
The distinction matters for Medincell’s business model because the company operates primarily through technology development, partnerships, licensing arrangements and product-related royalties rather than relying on a large independent pharmaceutical sales organisation. This structure allows commercial partners to undertake major responsibilities associated with regulatory development, manufacturing and product distribution. Medincell can subsequently participate in commercial performance through negotiated royalty and milestone arrangements.
Under the Weltruza agreement, Medincell is entitled to mid- to high-single-digit royalties on worldwide net sales. The company is also eligible for up to $112 million in development and commercial milestone payments, including the $4 million milestone associated with United States approval and up to $105 million in sales-based commercial milestones. Those sales-related payments remain contingent on specified thresholds and should not be treated as committed cash receipts.
The royalty arrangement creates the potential for a continuing revenue contribution as commercial sales develop. However, the absolute value of future royalties will depend on realised net sales, applicable royalty rates and the commercial terms governing the partnership. Regulatory approval removes a major development uncertainty, but it does not establish the product’s eventual sales trajectory.
The collaboration also strengthens the strategic relationship between the two companies. For Teva, it adds another differentiated schizophrenia treatment to its neuroscience portfolio, while Medincell gains a second marketed product through an established commercial partner. Whether the partnership produces a substantially larger revenue base will depend on prescribing adoption and the ability to sustain commercial growth after the initial launch.
Why does Uzedy’s sales performance matter when assessing Weltruza’s commercial potential?
Uzedy provides an existing commercial reference point for evaluating the Medincell and Teva partnership. In July 2026, Teva reported that United States net sales of Uzedy reached $77 million during the second quarter, representing growth of 43% compared with the corresponding period in 2025. The company also increased its 2026 Uzedy revenue outlook to between $270 million and $290 million, reflecting stronger expectations for its established injectable schizophrenia franchise.
For Medincell, this growth has already begun translating into recurring royalty income. During its financial year ended March 31, 2026, the company reported €9.3 million in Uzedy royalties within total revenue of €24.3 million. The figures demonstrate that the licensing model can generate meaningful income after a partnered product gains regulatory approval and begins expanding commercially.
Uzedy’s sales trajectory does not provide a direct forecast for Weltruza because the medicines contain different active ingredients and may serve overlapping but distinct patient populations. Prescribing decisions will depend on treatment history, efficacy considerations, adverse-event profiles, patient preferences and the availability of competing long-acting antipsychotics. It would therefore be inappropriate to assume that Weltruza will reproduce Uzedy’s growth rate or achieve comparable sales simply because both products use the same delivery platform.
The operational experience gained through Uzedy could nevertheless support aspects of Weltruza’s commercial introduction. Teva already has experience marketing long-acting schizophrenia treatments, engaging psychiatric prescribers and navigating relevant reimbursement arrangements. That infrastructure may reduce some organisational barriers, although product-specific market access and prescriber education will still be necessary.
For Medincell, two approved medicines also reduce dependence on a single commercial asset. Revenue concentration will remain an important consideration while Weltruza is in its early launch phase, but sustained sales from multiple products could make the company’s royalty income more diversified over time. The degree of diversification will become clearer only when Weltruza begins contributing measurable sales.
What will determine whether Weltruza gains traction against established schizophrenia injectables?
The United States long-acting antipsychotic market includes several established products based on risperidone, paliperidone, aripiprazole and other active ingredients. These medicines differ in injection interval, route of administration, initiation requirements, adverse-event profile and clinical familiarity. Weltruza enters this market with a differentiated olanzapine formulation rather than a new antipsychotic mechanism.
Its potential advantage lies in making an established medicine available through a once-monthly subcutaneous injection without mandatory routine post-injection observation. This may be particularly relevant to clinicians who consider olanzapine appropriate but have concerns about the practical requirements associated with existing long-acting olanzapine injections. Nevertheless, the choice of antipsychotic remains highly individualised, and metabolic tolerability may influence treatment selection as strongly as dosing convenience.
Reimbursement will be another important commercial variable. Long-acting injectable antipsychotics can involve specialty pharmacy arrangements, medical-benefit billing, clinic administration and payer-specific coverage requirements. Teva will need to ensure that providers can obtain the product and that patients have appropriate access through their insurance or other payment arrangements.
Pricing and patient access will therefore influence how quickly prescribing expands beyond the initial launch period. The October 9 announcement did not establish comprehensive payer coverage, actual net selling prices or confirmed prescription volumes. Commercial adoption should not be inferred solely from regulatory approval or the expectation of near-term product availability.
Prescriber confidence will also depend on practical experience with the formulation. Injection-site tolerability, dose selection, management of adverse reactions and continuity of treatment will be relevant to clinicians incorporating Weltruza into long-term care. Evidence showing that patients remain engaged with treatment over repeated dosing cycles could eventually provide a more informative measure of the product’s real-world value than initial prescription numbers alone.
How did investors react to the FDA decision, and what does the market response indicate?
Investors reacted positively to the approval announcement on October 9, with Medincell shares closing at €29.06 on Euronext Paris, an increase of 16.89% from the previous session’s €24.86 closing price. The stock reached an intraday high of €32.38 before retreating, indicating that the initial market response was stronger than the final closing gain. Trading had been temporarily suspended earlier in the session at the company’s request and resumed at 2:45 p.m. Paris time following the regulatory announcement.
Teva Pharmaceutical Industries also recorded a positive market reaction, with its New York-listed American depositary shares closing at $41.10, up 4.71% from $39.25 in the preceding session. The gains coincided with the FDA approval and reflected renewed attention to the company’s innovative neuroscience portfolio. However, the share-price movements should not be interpreted as a precise market valuation of Weltruza, since broader investor expectations and company-specific factors also influence trading.
The size of Medincell’s percentage gain is particularly relevant given the company’s smaller scale and royalty-focused business model. A newly approved partnered product can materially change expectations for future milestone income and recurring revenue, even when the ultimate commercial opportunity remains uncertain. For Teva, the potential contribution from Weltruza must be evaluated within a much larger pharmaceutical portfolio.
Medincell’s financial position provides additional context. Its results for the year ended March 31, 2026 showed an operating loss of €20.8 million alongside €84.8 million in liquidity, comprising cash, cash equivalents and low-risk financial investments. The company had also completed a €48.2 million financing in March 2026, supporting investment in its broader pipeline while royalty contributions continued to develop.
The approval strengthens the visibility of future potential income, but it does not eliminate Medincell’s need to manage development spending and financial commitments. Investors will increasingly be able to assess the company against measurable commercial performance rather than relying primarily on regulatory probabilities and pipeline expectations.
Could European approval provide another commercial opportunity for Weltruza?
Weltruza’s international development programme remains relevant following the United States decision. In May 2026, the European Medicines Agency accepted the marketing authorisation application for the olanzapine long-acting injectable formulation intended for adults with schizophrenia. The European submission is supported by the clinical development programme that includes SOLARIS, but acceptance of the application represents the beginning of formal review rather than approval.
As of October 11, 2026, the medicine had not received European marketing authorisation. Any future European commercial launch would require completion of the applicable regulatory assessment and the necessary authorisation process. Reimbursement and national market-access decisions would create additional steps before widespread patient availability.
For Medincell, international commercialisation could broaden the geographical base supporting future royalty income. However, the timing and scale of any European contribution remain dependent on regulatory outcomes and subsequent launch decisions. The worldwide royalty arrangement establishes a potential economic interest in sales outside the United States, but does not guarantee that the product will obtain authorisation or achieve commercial success in every market.
What are the next milestones for Medincell and Teva after the Weltruza approval?
The immediate milestone is the planned United States commercial availability of Weltruza, which Teva expects in the weeks following the October 9 approval. Initial launch activity will provide information about distribution readiness, prescriber access and the practical implementation of the product’s dosing and administration requirements. The companies have not yet disclosed an established commercial prescription base for Weltruza or a confirmed long-term revenue trajectory.
For clinicians, the important questions will involve real-world tolerability, metabolic monitoring, injection-site reactions and the experience of patients receiving repeated monthly doses. Continued pharmacovigilance will also be necessary to identify uncommon adverse events, including any potential post-injection reactions that were not observed during the clinical development programme. The absence of mandatory routine post-injection monitoring represents a practical distinction, but it does not remove the need for appropriate clinical oversight.
For Teva Pharmaceutical Industries, the launch adds a second Medincell-enabled medicine to its schizophrenia treatment franchise alongside Uzedy. The company will need to demonstrate that Weltruza can reach clinicians and patients for whom its particular formulation offers a meaningful treatment option. Commercial performance will depend on product availability, reimbursement, patient selection and the degree to which convenience advantages influence prescribing decisions.
For Medincell, the approval creates a near-term $4 million milestone entitlement and the potential for additional royalties and commercial milestones as sales develop. The more important longer-term test will be whether Weltruza can join Uzedy as a sustained contributor to recurring revenue, supporting the company’s wider pipeline investments and licensing strategy. With two FDA-approved medicines now using its drug-delivery technology, Medincell has moved beyond demonstrating that its platform can produce an approved treatment; the next measure of success will be how effectively those products perform in competitive pharmaceutical markets.
